[Porphyria cutanea tarda following treatment with depot estrogens in patients with prostate cancer].

In 3 out of 133 patients suffering from prostatic cancer and treated with depot estrogens a porphyria cutanea tarda was found after a follow-up ranging from few months to 10 years. Therefore, a defect of the uroporphyrinogen decarboxylase has been postulated. The therapy could be continued under small doses of chlorochin diphosphate.